{"filing":{"accession_number":"0001193125-26-296200","cik":"0001111485","ticker":"RXST","company_name":"RxSight, Inc.","form":"8-K","filing_date":"2026-07-06","report_date":null,"primary_document":"rxst-20260706.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1111485/000119312526296200/rxst-20260706.htm"},"events":[{"id":17060,"run_id":15273,"accession_number":"0001193125-26-296200","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"RxSight issued a press release on July 6, 2026 announcing preliminary unaudited second quarter 2026 financial results, including total company revenue of approximately $32–$34 million, LAL unit sales of 24,917 units, and cash position of approximately $209 million. The filing is disclosed under Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes updated 2026 full-year guidance ($140–$160 million revenue) and gross margin expectations, making it a material financial results announcement.","company_name":"RxSight, Inc.","ticker":"RXST","filing_date":"2026-07-06","form":"8-K","submitted_at":null,"items":[{"id":15362,"accession_number":"0001193125-26-296200","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"RxSight issued a press release on July 6, 2026 announcing preliminary unaudited second quarter 2026 financial results, including total company revenue of approximately $32–$34 million, LAL unit sales of 24,917 units, and cash position of approximately $209 million. The filing is disclosed under Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes updated 2026 full-year guidance ($140–$160 million revenue) and gross margin expectations, making it a material financial results announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:48:39.499687+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15362,"accession_number":"0001193125-26-296200","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"RxSight issued a press release on July 6, 2026 announcing preliminary unaudited second quarter 2026 financial results, including total company revenue of approximately $32–$34 million, LAL unit sales of 24,917 units, and cash position of approximately $209 million. The filing is disclosed under Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes updated 2026 full-year guidance ($140–$160 million revenue) and gross margin expectations, making it a material financial results announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:48:39.499687+00:00","company_name":"RxSight, Inc.","ticker":"RXST","filing_date":"2026-07-06"}]}